Asthma is characterized by chronic inflammation, dysregulated antioxidant pathways, and airway smooth muscle hyperplasia and hyperresponsiveness. For decades, therapies have relied on inhaled corticosteroids and b-agonists, yet nearly 40% of asthmatics have inadequate control of their symptoms leading many patients (70%) to turn to complementary medicines like ginger to control their symptoms. Purified gingerols and shogaols (<i>e.g</i>. 6-shogaol) are recognized bioactive components of ginger which we have demonstrated modulate multiple components of the asthmatic response including a reduction in inflammation, a relaxation of airway smooth muscle and modulation of anti-oxidant pathways.  These primary components of ginger are extensively metabolized when taken orally.  We are investigating whether these metabolites, as well as metabolite-inspired novel derivatives, have enhanced potency of controlling asthma phenotypes in humans and murine models of asthma.

Targeting airway hyperresponsiveness and lung inflammation in asthma with derivatives of bioactive components of ginger

Fall 2022 abstracts, posters, and presentations will launch in mid-September.

ACS Fall 2022

The official archive and repository for all ACS Meetings & Expositions abstracts and select posters or presentations.